Illinois SB1773 (104th General Assembly), which would amend the Illinois Controlled Substances Act to classify xylazine as a Class/Schedule III controlled substance and include specific statutory exemptions for certain veterinary/animal-drug and professional uses, advanced procedurally in the Illinois House. The ILGA bill status record shows the bill was placed on the House Calendar for 2nd Reading (Short Debate) on 2026-02-13. This is legislative progress and not enactment; compliance teams should treat the requirements as pending and monitor for passage, signature, and any finalized effective/implementation dates.
The Illinois General Assembly status record for SB1773 shows the bill’s latest action as of 2/13/2026: ‘House: Placed on Calendar 2nd Reading – Short Debate.’ This is a legislative progress update indicating the proposal to amend the Illinois Controlled Substances Act (including xylazine scheduling and related provisions) remains pending and has not been shown as enacted on the ILGA status page. Compliance teams tracking potential controlled-substance handling, distribution, and professional-use exceptions in Illinois should monitor for subsequent House action and any enactment (Public Act) before treating requirements as in force.
Per the official ILGA bill record, SB1773 proposes to amend the Illinois Controlled Substances Act to add xylazine as a Class III controlled substance (effective date stated in the bill synopsis as January 1, 2026). The ILGA full-text for Senate Committee Amendment No. 4 includes a new Section 720 ILCS 570/309.1 (‘Xylazine exemptions’) specifying circumstances where xylazine ‘shall not be considered a controlled substance’ (e.g., certain FDA-approved/permitted animal-drug uses by licensed Illinois veterinarians, API manufacturing for approved animal drugs, use by certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinary supervision). Compliance teams should treat this as a pending change until enacted, but should assess potential impacts on controlled-substance controls and professional-use carve-outs for xylazine in Illinois if the bill becomes law.
An Illinois SB1773 committee amendment (sam003), filed 2025-04-01, provides detailed statutory exemption language (new Section 309.1) stating that, notwithstanding the Schedule/Class III scheduling of xylazine, xylazine is not considered a controlled substance when used/handled under specified conditions (including certain licensed veterinarian use for nonhuman species involving FDA-approved animal drugs, use as an API for manufacturing an FDA-approved animal drug, use by licensed certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinarian supervision). Compliance teams should use the amendment text to assess whether current/anticipated xylazine activities would fall under exemptions if SB1773 is enacted.